

# UPDATE REGULATORY FRAMEWORK SoHO

Johan Guns

# NEW EU REGULATION



Official Journal  
of the European Union

EN  
L series

2024/1938

17.7.2024

**REGULATION (EU) 2024/1938 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL**



**of 13 June 2024**

**on standards of quality and safety for substances of human origin intended for human application  
and repealing Directives 2002/98/EC and 2004/23/EC**




Revision of the law of 2008


# NEW EU REGULATION




# SCOPE REGULATION



# ENTITY AND ESTABLISHMENT



# TECHNICAL GUIDELINES



# EDQM GUIDE

## Position of good practice guidelines

### Standards

Tissue and cell (TC) entities must establish, maintain and update a quality management system, appropriate to their activities, achieving a high level of quality of tissues and cells. ([Article 37.1](#))

### GPGs


2.1.2 Each TC entity and tissue establishment (TE) should develop, document and maintain a QMS which facilitates meeting all the relevant standards and good practice guidelines of this Guide and with the requirements of national and, for EU Member States, EU legislation.

### Recommendations

The basic concepts of quality management, good practice and quality risk management are interrelated and interconnected. They are described here in order to emphasise their relationships and their fundamental importance to all activities.

A good QMS may address quality management under the following headings:

# EURO GTP-2 AND MiRCA






# The authorisation pathway for SoHO preparations

Consider relevant EDQM monographs

- a) Systematic **Benefit/Risk Assessment** by the SoHO establishment, in order to determine the available evidence on safety, quality and effectiveness, possibly through EURO GTP tool
- b) Submission of an **application**, including **laboratory validation** and other safety, quality and effectiveness data and, where relevant, a **clinical outcome monitoring plan** proportionate to risk


c) **Assessment** of the application by the competent authority




d) **Assessment** by the competent authority of evidence of safety, quality and effectiveness data gathered in clinical outcome monitoring



# CHANGE MANAGEMENT



# RISK/BENEFIT BALANCE



# SOHO PREPARATIONS



# FAMHP AND SUPERIOR HEALTH COUNCIL

SAER

Superior Health Council – 3 advices

Federal agency – 8 new forms

DANK U



VRIJE  
UNIVERSITEIT  
BRUSSEL



Universitair  
Ziekenhuis  
Brussel